You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).

Figure INF-6:  Estimated HCV antibody prevalence among injecting drug users – studies with national and sub-national coverage – Part (ii) Young injecting drug users (under age 25), 2003 to 2004

Figure INF-06 part ii

Notes:

Black square = samples with national coverage; blue triangle = samples with subnational (including local or regional) coverage

Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Data for Slovenia are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Reitox national focal points. For primary sources, study details and data before 2003, see Table INF-12.